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Abstract
Objective: To investigate whether interleukin-6 (IL-6) and interleukin-8 (IL-8) can be used as the
evaluating indices of dialyzer biocompatibility.
Methods: The levels of plasma IL-6 and IL-8 were measured by the sandwich enzyme linked
immunosorbent assay (ELISA) method in 15 hemodialysis (HD) patients with end-stage renal failure
(ESRF) before and post HD. Those patients were randomly divided into three groups according to
the dialysis membrane used: cellulose acetate (CA) membrane group, Hemophan (HE) membrane
group and polysulfone (Psu) membrane group respectively. Another five non-HD (NHD) ESRF patients
and five healthy subjects were selected as controls.
Results: The plasma of IL-6 and IL-8 levels in the CA and HE groups were significantly higher than
that of patients in the Psu group, NHD patients and normal subjects (p < 0.05). Moreover, no
significant difference could be demonstrated in the plasma IL-6 and IL-8 concentrations between
patients in the CA and HE groups (p > 0.05), and among patients in the Psu group, NHD patients
and normal subjects (p > 0.05). There was also no difference in the levels of IL-6 and IL-8 in
patients dialyzed with the three different dialyzers between pre- and post-dialysis. However, a
significant positive linear correlation existed between the plasma IL-6 and IL-8 levels (p < 0.05).
Conclusions: Our results suggest that the levels of plasma IL-6 and IL-8 were related to the type of
dialyzers and could be used as indices evaluating the biocompatibility of dialyzers. Furthermore,
the change of one cytokine can indirectly reflect the tendency of the other.
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IL-6 and IL-8 in hemodialysis
INTRODUCTION
With the development of the hemodialysis (HD)
technique, many investigators have focused on how to
improve the biocompatibility of dialyzers by applying
various biologic techniques (1). Cytokines such as
interleukin-6 (IL-6) and interleukin-8 (IL-8), mainly
derived from peripheral blood mononuclear cells
(PBMC), are thought to contribute to some acute or
chronic complications associated with maintenance HD,
including hypertension, fever, anorexia, muscle atrophy,
amyloid degeneration, osteoporosis, etc. (2). The
induction of the cytokine production is dependent on the
nature of the dialysis membrane used in HD patients.
Therefore, cytokine level is often used as an index of
biocompatibility of dialyzers. Previously, C3a, C5a, IL-
1, and tumor necrosis factor alpha (TNF-α) have been
extensively studied with regard to their possible
involvement in the complications associated with HD
that used less biocompatible dialyzers. However, the
effect of dialysis membranes on both IL-6 and IL-8
production has not yet been studied. To determine
whether dialyzer biocompatibility could be evaluated by
these cytokines, we measured the plasma IL-6 and IL-8
levels in end-stage renal failure (ESRF) patients who
were treated with HD by using different dialysis
membranes.
MATERIAL AND METHODS
Patients
Fifteen patients (7 males and 8 females, mean age 52.5
±5.2 years) undergoing maintenance HD at the Blood
Purification Center, First Teaching Hospital, China
Medical University were investigated. Eleven patients
had chronic glomerulonephritis, two patients had
nephrosclerosis, one patient had bilateral ureteric
stenosis, and the renal diagnosis was unknown in one
patient. The duration of dialysis ranged from 3 to 63
months (mean 21.6 ±17.2). They were receiving HD
treatment two or three times a week for 4.5 hours per
session. The patients were randomly divided into three
groups: five patients dialyzed with Hemophan (HE)
membrane (Akzonobel, 1.3 m2), five with cellulose
acetate (CA) membrane (Alethine Medical AB, 1.3 m2)
and five with polysulfone (Psu) membrane (Fresenius
Medical Care, 1.3 m2). All dialyzers were reused twice,
each after disinfection by formalin. Five milliliters of
heparinized blood were drawn before starting and
immediately following dialysis at least 2 weeks after the
assigned dialyzer was used. All patients received the
same centrally distributed dialysate concentrate, and the
same reverse osmosis water. Bacteriological and
endotoxin controls of the water were done once every
week. During the study period, the bacterial count was
below 100 CFU/mL, and the endotoxin level was always
below 0.01 endotoxin unit/mL. All patients had no active
infection or immunological diseases and received no
blood transfusion, hormone replacement, or cytotoxic
therapy in the preceding month. Another five patients (2
males, 3 females), ranging in age from 23 to 54 years
(mean 37.2 ±13.9), all suffering from chronic
glomerulonephritis at ESRF without dialysis therapy
were recruited as the uremia-non-HD (NHD) group. Five
healthy volunteers (2 males and 3 females), ranging in
age from 26 to 45 years (mean 34.8 ±5.7), served as
controls. All samples were kept at -40 oC until processing.
Assay for IL-6 and IL-8
We measured the plasma concentrations of IL-6 and
IL-8 by the enzyme linked immunosorbent assay  (ELISA
[Shenggong Biochem Corp. Shanghai, China]) in all
patients. For the IL-6 assay, we added undiluted plasma
(50 µl) to each ELISA plastic well coated with anti-IL-6
monoclonal antibody to human after adding assay buffer.
The mixture was incubated at room temperature for 1
hour. After removing the test specimen, the wells were
washed three times with washing solution provide by
the kit. After adding horseradish-peroxidase-labeled
monoclonal antibody to human IL-6 Fab in phosphate
buffered saline, the microplate was incubated at room
temperature for 30 minutes. After removing the reaction
solution the wells were again washed three times with
washing solution. Sodium acetate-citrate buffered was
added and the microplate was incubated at room
temperature for 30 minutes. After adding 1M H2SO4 to
stop the reaction, the absorbency of the reaction mixture
was measured at 450 nm using ELISA meter (Model
550). Concentration of IL-6 was calculated according to
the standard curve. The sensitivity of the assay was 1
pg/mL. The method of assay plasma IL-8 was similar to
that of IL-6.
Statistics
The results were expressed as mean values ±standard
error of mean. Statistical analysis of pre- and post-HD
was performed using paired Student's t-test. The IL-6
and IL-8 levels of groups were analyzed by analysis of
variance (ANOVA).
RESULTS
The plasma IL-6 and IL-8 levels are summarized in
figure 1 and table 1. There was no significant difference
in plasma IL-6 and IL-8 levels of the NHD group and
controls. The concentrations of plasma IL-6 and IL-8 in
dialysis patients exposed to HE membranes and CA
membranes increased significantly when compared with
those exposed to Psu membrane (p < 0.05) (Table 1). No
statistical difference was obtained between the HE group
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and the CA group. In addition, the plasma levels of IL-6
and IL-8 in the Psu group were similar to those in the
NHD group or controls.
In all the dialyzers tested, neither plasma IL-6 nor IL-8
levels had significant changes between pre-HD and post-
HD, as summarized in table 2. On the other hand, plasma
IL-6 and IL-8 levels before HD showed positive linear
correlation in the Psu as well as in the CA and HE groups
(p < 0.05 for each) (Fig. 2-4).
DISCUSSION
The dialyzer is one of the necessary parts in HD
equipment. The ideal dialyzer should be made of
materials with perfect biocompatibility. Biocompatibility
Table 1.  The comparison of plasma IL-6 and IL-8 levels*.
IL-6 (pg/mL) IL-8 (pg/mL)
Controls (n = 5) 16.45 ±3.44 18.47 ±3.33
NHD (n = 5) 15.55 ±1.99 20.46 ±4.80
HE group (n = 5) 28.23 ±10.701,2 29.75 ±3.05 1,2
CA group (n = 5) 24.99 ±3.39 1,2 28.38 ±2.85 1,2
Psu group (n = 5) 16.85 ±3.78 21.90 ±2.88
NHD = non-hemodialysis; HE = Hemophan; CA = cellulose acetate;
Psu = polysulfone
*The plasma cytokines values of the HE, CA, and Psu groups are
from pre-HD.
1p < 0.01 as compared with controls.
2p < 0.01 as compared with Psu group.
Figure 1.  The comparison of IL-6 and IL-8 plasma levels in each
group (pg/mL). The plasma cytokines values of the three HD groups
are from pre-HD.
Table 2.  Pre-HD and post-HD plasma IL-6 and IL-8 levels in the three HD groups.
IL-8 (pg/ml) IL-6 (pg/ml)
pre-HD post-HD pre-HD post-HD
HE group 23.28 ±10.70 31.04 ±9.37 29.75 ±3.05 30.87 ±4.15
CA group 24.99 ±3.39 28.92 ±8.20 28.38 ±2.85 29.64 ±3.98
Psu group 16.85 ±3.78 14.64 ±0.95 21.90 ±2.88 22.45 ±3.40
HD = hemodialysis; HE = Hemophan; CA = cellulose acetate; Psu = polysulfone
Figure 2.  The relationship of plasma IL-6 and IL-8 in HE group
before dialysis.
Figure 3.  The relationship of plasma IL-6 and IL-8 in Pus group
before dialysis.
Figure 4.  The relationship of plasma IL-6 and IL-8 in CA group
before dialysis.
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is defined as the specific or non-specific interaction
resulting from the blood coming in contact with artificial
materials. The demonstrable indices for the evaluation
of dialyzer biocompatibility include coagulation,
fibrinolysis, complements, kininogen-kallikrein, the
activation of blood cells such as neutrophils, monocytes,
lymphocytes, platelets etc. Since the "interleukin
hypothesis" was proposed by Henderson et al (3), it had
attracted attention regarding whether various cytokines
could be considered as indices for evaluation of
biocompatibility.
Both IL-6 and IL-8 have many biological functions as
shown by many researches. IL-8 consists of 72 amino
acids with a molecular mass of 8 KD. It is mainly secreted
by monocytes-macrophage lineage, and is a specific
chemotactic factor for neutrophils, T lymphocyte, and
basophils. It can cause neutrophil degranulation and
release of lysosome enzymes. It also stimulates basophils
to release histamine and leukotriene C4. IL-6, molecular
mass 26 KD, is mainly derived from monocytes. It can
promote the proliferation of myeloid stem cells, the
differentiation of B cell to secret immunoglobulin, the
activation of T cell, and the production of acute reactive
proteins and other cytokines, such as IL-1, TNF-α (4).
Thus IL-6 and IL-8 play important roles in human
immunologic function. However, evidence on how the
two cytokines fluctuate in chronic HD patients and
whether they could be used as indices of dialyzer
biocompatibility have not been thoroughly studied. Some
studies indicate that the serum levels of IL-6 and IL-8 in
HD patients decreased or remained unchanged, but there
is also evidence to the contrary (5). It is generally
considered that high levels of IL-6 and IL-8 contribute
to the chronic inflammatory stimulation of dialysis to
HD patients. Other researchers have observed that a
single session HD could prominently affect the secretion
of cytokines(6).
In our study we found that the IL-6 and IL-8 levels in
the HE and CA groups were much higher than levels in
the control, NHD and Psu groups, and that there was no
difference in the levels of plasma IL-6 and IL-8 among
the Psu group, the NHD group and controls. So we
presumed that the high levels of IL-6 and IL-8 in the CA
or HE groups might indicate that these dialyzers were
less biocompatible than Psu. This conclusion conforms
to the results of other studies, which suggest a possible
role of IL-6 and IL-8 in estimating the biocompatibility
of dialyzers. The comparison of IL-6 or IL-8 levels before
and after HD brought out no statistical difference, which
was similar to the results of Yamaguchi et al (5).
Therefore, we supposed long-term HD, rather than a
single session might increase the levels of IL-6 and IL-8.
In addition, we found the IL-6 levels closely correlated
to the IL-8 levels in all the three HD groups. Therefore,
determining one of the cytokine levels could reflect the
level of the other.
The increased levels of IL-6 and IL-8 in HD patients
with dialyzers of poor biocompatibility, such as HE and
CA, may be due to the following factors: 1. Dialyzers
directly stimulate PBMC to secrete those cytokines (7);
2. Dialyzers can activate complements in the extra-
corporeal circuit, during which C3a, C5a and the end
production of C5b-9 may accelerate the secretion of
cytokines (8); 3. The lipopolysaccharide content in
dialysate can possibly activate PBMC to secrete
cytokines; 4. Other cytokines, such as IL-1 and TNF-α,
can modulate the secretion of IL-6 and IL-8 by acting
on PBMC.
The chronic interactions between blood and dialyzers
with poor biocompatibility can induce immune disorders,
which plays a possible role in the pathogenesis of chronic
complications related to HD. For example, IL-6 can
enhance the formation of osteoclast and promote
osteolysis (9), which may contribute to the generation
and development of osteoporosis in HD patients. In
addition, interactions between IL-6 and monocyte can
promote the synthesis and release of ß2-microglobulin,
which is associated with amyloid deposition in long-term
HD patients (10). Additionally IL-6 is regarded as an
autocrine growth factor, which may have a role in the
pathogenesis of renal tumor in patients suffering from
ESRF (11). On the other hand, IL-8 is a chemotactic
factor of neutrophils, T cell and basophiles, and may play
an important role in inflammatory reaction. The high
plasma level of IL-8, presumably secreted by PBMC,
possibly explains the vulnerability of HD patients to
infection. Because IL-6 and IL-8 may be involved in the
pathogenesis of dialysis complications, their abnormal
activation may be of direct clinical significance. In
conclusion, it may be valuable to consider IL-6 and IL-8
as indices for evaluation of dialyzer biocompatibility.
In summary, HE or CA membranes might increase
plasma IL-6 and IL-8 levels in maintenance HD. IL-6
and IL-8 can be used as the indices of dialyzer
biocompatibility. Furthermore, the plasma level of one
cytokine can reflect the level of the other.
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